About 100 reports

Asthma and Cancer This report covers market opportunities based on pipeline developments for six key therapeutic specialities: Alzheimer' s Disease Asthma Breast Cancer Leukemia Lung Cancer Lymphoma These six areas are expected to show the strongest pipeline impact and c

  • Lymphoma
  • Oncology
  • Pathology
  • World
  • Market Size

RECENTLY, CONSIDERING THE TOP DRUG FAILURES IN THE CLINICAL TRIALS, MOST OF THEM ARE CANCER INDICATIONS, FOLLOWED BY TWO FOR RHEUMATOID ARTHRITIS CANDIDATES, AND ONE EACH FOR INVESTIGATIONAL HEART DISEASE, DEPRESSION, AND ASTHMA DRUGS.

  • Lymphoma
  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Idec Inc.
  • Bristol-Myers Squibb Company
  • Scope and Methodology

ASTHMA IS UNDER-DIAGNOSED AND UNDER-TREATED.

  • Lymphoma
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • 7.3. FORECAST METHODOLOGY
  • XENCOR

THE DRUG IS CURRENTLY BEING DEVELOPED IN PHASE III FOR ASTHMA AND COPD.

  • Lymphoma
  • New Caledonia
  • MedImmune, LLC
  • Roche Group
  • Xencor, Inc.
  • DRUGS BASED ON XMAB® ANTIBODY TECHNOLOGY

THIS DRUG HAS NOW REACHED PHASE III OF CLINICAL DEVELOPMENT FOR THE TREATMENT OF ASTHMA AND COPD., ##. ##. ##. ##. ##.

  • Lymphoma
  • United States
  • Amgen Inc.
  • MedImmune, LLC
  • Novartis AG

THE COMPANY IS ALSO INVESTIGATING THE POTENTIAL OF THIS TECHNOLOGY TO TREAT OTHER CLINICAL INDICATIONS, SUCH AS GRAFT VERSUS HOST DISEASE, MULTIPLE SCLEROSIS (MS), CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INFLAMMATORY BOWEL DISEASE (IBD) AND STEROID RESISTANT ASTHMA. ##. ##. ##. ##.

  • Lymphoma
  • United States
  • Juno Therapeutics Inc.
  • Kite Pharma, Inc.
  • Novartis AG

IT IS ALSO WORTH HIGHLIGHTING THAT IMMUNOTHERAPY IS BEING STUDIED NOT ONLY TO TREAT CANCER, BUT ALSO FOR SEVERAL OTHER INDICATIONS INCLUDING ASTHMA, ALLERGY AND ALZHEIMER' S DISEASE.

  • Lymphoma
  • United States
  • Cellectis S.A.
  • Juno Therapeutics Inc.
  • Kite Pharma, Inc.

IMMUNOTHERAPY IS BEING STUDIED NOT ONLY TO TREAT CANCER, BUT SEVERAL MORE INDICATIONS INCLUDING ASTHMA, ALLERGY AND ALZHEIMER' S DISEASE. ##. ##. ##.

  • Lymphoma
  • United States
  • Agenus Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • MOGAMULIZUMAB - DRUG PROFILE
  • MOGAMULIZUMAB - DRUG PROFILE

The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG ## in asthma subjects that would preclude further development of AMG ##.

  • Lymphoma
  • Therapy
  • United States
  • World
  • Kyowa Hakko Kirin Co., Ltd.
  • PIPELINE BY AB SCIENCE SA, H1 2017
  • DORMANT PRODUCTS, H1 2017 (CONTD..1), H1 2017

LAS-## - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description LAS-## ALMIRALL SA NA NA LAS-## IS UNDER DEVELOPMENT FOR THE TREATMENT OF ASTHMA.

  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Portola Pharmaceuticals, Inc.
  • Breast Cancer
  • PANCREATIC DUCTAL ADENOCARCINOMA

It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • Breast Cancer
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2017 (CONTD..1), H1 2017

The company offers its products for the treatment of airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases of the lung.

  • Digestive System Disorder
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • MOGAMULIZUMAB - DRUG PROFILE

The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG ## in asthma subjects that would preclude further development of AMG ##.

  • Lymphoma
  • Therapy
  • Japan
  • Product Initiative
  • Kyowa Hakko Kirin Co., Ltd.
  • Multiple Myeloma (Kahler Disease)
  • Pipeline by Rhizen Pharmaceuticals S.A., H2 2016

As of September 2014, it was in phase II stage of development for mild allergic asthma.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • MORPHOSYS RAISES USD124.3 MILLION IN PRIVATE PLACEMENT OF SHARES
  • MORPHOSYS COMPLETES PRIVATE PLACEMENT OF SHARES FOR US$112.7 MILLION

It drugs are used in the treatment of different types of cancer, psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, solid tumors, eye disease, and other inflammatory diseases.

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • United States
  • MorphoSys AG
  • Lung Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Acetylon Pharmaceuticals, Inc.

Genentech dosed the first patient in a Phase I dose-escalation clinical trial in healthy volunteers and asthma patients with an investigational medicine to target inflammation associated with asthma.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Company
  • Genentech, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.

A Phase II randomized, double blind, placebo-controlled, crossover study to evaluate the safety and efficacy of eculizumab in subjects with mild allergic asthma was initiated in September 2007.

  • Lymphoma
  • Mental Health
  • United States
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.

This patent, which expires in 2032 protects to the use of masitinib in the treatment of severe persistent corticosteroid-dependent asthma and severe persistent corticosteroid-resistant asthma.

  • Lymphoma
  • Monoclonal Antibody
  • Neurological Disorder
  • Therapy
  • AB Science SA

Its pharmaceutical products comprise inhaled corticosteroid for asthma, osteoporosis drugs, anti-hyperuricemia agent, and others.

  • Lymphoma
  • Therapy
  • Europe
  • World
  • ChemoCentryx, Inc.

This patent, which expires in 2032 protects to the use of masitinib in the treatment of severe persistent corticosteroid-dependent asthma and severe persistent corticosteroidresistant asthma.

  • Dermatological Condition
  • Lymphoma
  • Therapy
  • United States
  • Product Initiative

This patent, which expires in 2032 protects to the use of masitinib in the treatment of severe persistent corticosteroid-dependent asthma and severe persistent corticosteroidresistant asthma.

  • Dermatological Condition
  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Blood Disease
  • Hospital
  • Lymphoma
  • Vaccine
  • Merck & Co., Inc.

This observation supports the link between IL-## and periostin in asthma.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • United States
  • Chugai Pharmaceutical Co., Ltd.
  • MEDI-570 - DRUG PROFILE
  • PERIPHERAL T-CELL LYMPHOMAS (PTCL) - PIPELINE BY RHIZEN PHARMACEUTICALS S.A., H2 2016

AB Science SA announced Phase II results of masitinib in severe asthma uncontrolled by oral corticosteroids.

  • Chemotherapy
  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2016 (CONTD..1)

CKD-## is under development for the treatment of rheumatoid arthritis, systemic lupus erythematosus, asthma, Crohn disease, inflammatory bowel s disease, ulcerative colitis and multiple sclerosis.

  • Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Acetylon Pharmaceuticals, Inc.

In addition, Infinity paid Millennium the USD## million development milestones for the August 2012 initiation of the Phase IIa clinical trial of IPI-## in patients with asthma.

  • Lymphoma
  • United States
  • Company
  • Company Operations
  • Infinity Pharmaceuticals, Inc.
  • PIPELINE BY AURIGENE DISCOVERY TECHNOLOGIES LTD, H2 2017

Its clinical development pipeline includes alectinib and Erlotinib for metastatic non-small cell lung cancer; Anti-ST## for asthma; etrolizumab for ulcerative colitis; atezolizumab for solid tumors and metastatic melanoma; obinutuzumab for non-Hodgkin lymphoma; and pertuzumab for breast canc

  • Leukemia
  • Lymphoma
  • United States
  • Product Initiative
  • Karyopharm Therapeutics Inc.

Rhizen Pharma' s products find application in the treatment of diseases such as solid tumors, B cell lymphomas, hematological malignancies, asthma, diabetes and chronic obstructive pulmonary disease, among others.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Company Operations
  • TG Therapeutics, Inc.